Lipoproteins from uremic patients on continuous ambulatory peritoneal dialysis are more resistant to oxidative modification

1999 ◽  
Vol 144 ◽  
pp. 41
Author(s):  
A.P. Serdyuk ◽  
R.E. Morton
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Oxidative Modification ◽  
Uremic Patients

Histologic Change of Peritoneal Membrane in Relation to Adequacy of Dialysis in Continuous Ambulatory Peritoneal Dialysis Patients

2003 ◽  
Vol 23 (2_suppl) ◽  
pp. 26-30 ◽  
Author(s):  
Irini Savidaki ◽  
Dionisios Karavias ◽  
Florentia Sotsiou ◽  
Sotiria Alexandri ◽  
Pantelitsa Kalliakmani ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Structural Changes ◽  
Mesothelial Cells ◽  
Peritoneal Membrane ◽  
Histologic Change ◽  
Significant Difference ◽  
Uremic Patients ◽  
Group B ◽  
Histologic Changes

Background Long-term exposure of peritoneal membrane to bioincompatible dialysis solutions leads to structural changes and loss of ultrafiltration capability. Objective We studied the possible relationship between histologic change and the transport characteristics of peritoneal membrane and adequacy of dialysis in continuous ambulatory peritoneal dialysis (CAPD) patients. Patients and Methods The study included 18 CAPD patients (11 men, 7 women) who underwent a peritoneal biopsy either at initiation of treatment (group A, n = 9) or after a mean of 4 years on CAPD (group B, n = 9). The morphologic changes in the mesothelial cells and the vascular compartment and the thickness of the submesothelial collagenous zone were estimated and compared with observations from 6 patients with normal renal function who underwent biopsy of the parietal peritoneum during abdominal surgery. The relationship of the observed changes in CAPD patients to results from a peritoneal equilibration test (PET) and to adequacy of dialysis [total weekly creatinine clearance (CCr) and Kt/V urea] were also investigated. Results The main histologic changes in both groups of patients were loss of mesothelial cells and decrease in the normal mesothelial surface, thickening of the submesothelial collagenous zone, and presence of vascular hyalinosis. The thickness of the submesothelial collagenous zone in both groups of patients was significantly greater than that found in controls (410 μm and 580 μm vs 50 μm, p < 0.05). Although no significant difference was found between morphologic change in the peritoneal membrane of uremic patients starting on CAPD and those who had been on peritoneal dialysis (PD) for a mean period of 4 years, a trend was observed toward more severe lesions in the latter patients. The PET, CCr, and Kt/V urea were not significantly different in the two groups of patients. Those parameters also showed no significant changes when examined at initiation of CAPD and after a mean of 4 years of PD in the same patients (group B). No significant correlations were observed between the histologic changes and the PET, CCr, or Kt/V in both groups of patients. Conclusions Significant structural changes are observed in the peritoneal membrane of uremic patients, and those changes become worse with CAPD treatment. Structural changes are not followed by functional changes during the first 4 years on CAPD.

Dislipemia in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis: Pharmacological Therapy (Simvastatin) versus Hemodialysis

1993 ◽  
Vol 13 (2_suppl) ◽  
pp. 431-433 ◽  
Author(s):  
Roberto Marangoni ◽  
Fernando Civardi ◽  
Franceso Masi ◽  
Roberto Cimino ◽  
Luca Maltagliati ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Total Cholesterol ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Pharmacological Therapy ◽  
Apolipoprotein A ◽  
Previously Treated ◽  
Uremic Patients ◽  
Significant Change ◽  
Therapeutic Possibilities

Peritoneal dialysis can worsen disllpemia, which is frequent in chronically uremic patients. In order to verify the therapeutic possibilities, we retrospectively studied 20 chronically uremic patients who had been previously treated with continuous ambulatory peritoneal dialysis (CAPO) and who had developed an IV-type dislipemia. Twelve have continued CAPO treatment and have been simultaneously treated with simvastatin; 8 have withdrawn from CAPO and have begun HO, without any antidislipemic pharmacological support. The results, after 3, 6, 12, and 18 months of treatment, showed the following: In patients treated with CAPO and simvastatin, highly significant decreases were noted in total cholesterol (T-cho) and triglycerides (TG) (p<0.001), and highly significant increases were noted in HOL-cholesterol (HOL-cho) (p<0.005) and apolipoprotein-A 1 (Apo-A 1) (p<0.01). In patients treated with HO, only slightly significant decreases were noted in T-cho (p<0.01) and TG (p<0.02), a slightly significant increase in Apo-A1 (p<0.05), and no significant change in HOL-cho. Apollpoprotein-B showed no change in the two groups. Therefore, patients undergoing CAPO, with dislipemia only, can continue the treatment, because simvastatin is capable of correcting dislipemia, while those patients who have displemia as well as other complications strictly due to CAPO must abandon treatment and must be transferred to extracorporeal methods.

scholarly journals Comparative Analysis of Immunophenotypic Abnormalities in Cellular Immunity of Uremic Patients Undergoing Either Hemodialysis or Continuous Ambulatory Peritoneal Dialysis

Renal Failure ◽  
2005 ◽  
Vol 27 (3) ◽  
pp. 279-282 ◽  
Author(s):  
Ioannis Griveas ◽  
George Visvardis ◽  
Aleka Fleva ◽  
Dorothea Papadopoulou ◽  
Eftathios Mitsopoulos ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Comparative Analysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Cellular Immunity ◽  
Uremic Patients

scholarly journals Continuous Ambulatory Peritoneal Dialysis Improves Immunodeficiency in Uremic Patients

Nephron ◽  
1983 ◽  
Vol 35 (3) ◽  
pp. 209-210 ◽  
Author(s):  
F. Giacchino ◽  
F. Quarello ◽  
M. Pellerey ◽  
G. Piccoli
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Uremic Patients

Glutathionyl hemoglobin in uremic patients undergoing hemodialysis and continuous ambulatory peritoneal dialysis

2001 ◽  
Vol 59 (s78) ◽  
pp. 155-158 ◽  
Author(s):  
Fumio Takayama ◽  
Shuichi Tsutsui ◽  
Masanobu Horie ◽  
Kaoru Shimokata ◽  
Toshimitsu Niwa
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Uremic Patients

Epidermal Langerhans Cells in Uremic Patients on Hemodialysis or Continuous Ambulatory Peritoneal Dialysis

Nephron ◽  
1993 ◽  
Vol 65 (2) ◽  
pp. 278-283 ◽  
Author(s):  
Thomas Mettang ◽  
Peter Fritz ◽  
Jochen Weber ◽  
Christoph Machleidt ◽  
Eugen Hübel ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Langerhans Cells ◽  
Uremic Patients ◽  
Epidermal Langerhans Cells

The Need for Second-Generation Antihepatitis C Virus Testing in Uremic Patients on Continuous Ambulatory Peritoneal Dialysis

1993 ◽  
Vol 13 (2) ◽  
pp. 132-135 ◽  
Author(s):  
Yee-Yung Ng ◽  
Shou-Dong Lee ◽  
Shiao-Chi Wu ◽  
Wu Tse Liu ◽  
Wei-Lian Chia ◽  
...  
Keyword(s):  
Peritoneal Dialysis ◽  
Continuous Ambulatory Peritoneal Dialysis ◽  
Clinical Relevance ◽  
First Generation ◽  
Second Generation ◽  
Hcv Infection ◽  
Enzyme Immunoassays ◽  
Hcv Antibody ◽  
Uremic Patients ◽  
Chi Square Analysis

Objective To assess the prevalence and clinical relevance of a hepatitis C virus (HCV) infection in continuous ambulatory peritoneal dialysis (CAPD) patients by first (Ortho) and second-generation (Abbott and UBI) HCV antibody enzyme immunoassays. Design Thirty-two serum samples tested by first generation HCV antibody enzyme immunoassays (EIA's) were reevaluated using two second-generation HCV antibody EIA's. Basic demographic data, history of blood transfusions, and duration of hemodialysis and CAPD were reviewed. Results were analyzed by chi square analysis, Wilcoxon rank sum, and the paired t-test. Setting The medical college's affiliated teaching hospital. Results The prevalence of the antibody anti-HCV increases with the duration of previous hemodialysis, but not with the duration of CAPD. The positive detection of anti-HCV by second-generation HCV antibody EIA's was higher than first-generation EIA's (25% and 34.4% vs 12.5%). Conclusion The prevalence and clinical relevance of HCV infection can be more accurately studied using the second-generation assays in uremic patients.

Sign in / Sign up

Export Citation Format

Share Document